Lonza
Company Snapshot
Company Overview
Lonza is a biotechnology company helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. The company operates under four segments: Small Molecules, Biologics, Cell & Gene, and Capsules & Health Ingredients.
The Cell & Gene division includes three business areas: Cell & Gene Technologies, Personalized Medicine, and Bioscience. Cell & Gene Technologies (CGT) is focused on providing an integrated range of CDMO services that span the complete value chain of cell and gene therapy modalities (allogeneic and autologous therapies and viral vectors). CDMO services include 2D/3D cell culture and the latest exosome development and manufacturing technologies.
In 2017, Lonza invested in HansaBioMed Life Sciences, based in Tallinn (Estonia), and Exosomics Siena, an Italian start-up. These investments reinforced Lonza’s platform for developing next-generation research and therapeutic and diagnostic applications based on exosomes.
Financial Highlights (FY 2023)
This information is available for BCC Research members only.
Company's Business Segments
- Biologics : Mammalian, Microbial, Bioconjugates, mRNA, Drug product services
- Small Molecules : Drug substance, Particle engineering, Drug product development and manufacturing
- Cell and Gene : Development and manufacturing services, Products, Solutions, Testing and automation platforms
- Capsules and Health Ingredients : Wide range of animal-based vegetarian and clean label Capsugel capsule, Pre-clinical and clinical solutions, Specialized delivery applications
- Others
Applications/End User Industries
- Pharmaceuticals
- Nutraceuticals
- Biotech
